IMPAIRED ENDOGENOUS FIBRINOLYSIS: A MAJOR STIMULUS FOR CORONARY THROMBOSIS AND ATHEROGENESIS*

1 Davies M. The pathophysiology of acute coronary syndromes. Heart 2000; 83:361–6.

2 Rosenberg RD Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340:1555–64.

3 Thompson SG J Kienast Pyke SDM Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635–41.

4 Christie PD JM Edelberg Picard MH A murine model of myocardial microvascular thrombosis. J Clin Invest 1999; 104:533–9.

5 Xiao Q MJ Danton Witte DP Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci USA 1997; 94:10335–40.

6 Burke AP A Farb Malcolm GT Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly. N Engl J Med 1997; 336:1276–82.

7 Barbash GI HD White Modan M for the investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trials. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Circulation 1993; 87:53–8.

8De Chillou C, Riff P, Sadoul N Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: a multivariate analysis. J Am Coll Cardiol 1996; 27:1662–8.

9 Fox KAA AK Robison Knabb RM Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 1984; 72:1346–54.

10 DeWood MA J Spores Notske R Prevalence of total coronary artery occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897–902.

11 Prowse CV A Farrugia Boulton FE A comparative study using immunological biological assays of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. Thromb Haemost 1984; 51:110–14.

12 Ridker PM CL Gaboury Conlin PR Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 87:1969–73.

13 Webb DJ. The pharmacology of human blood vessels in vivo. J Vasc Res 1995; 32:2–15.

14 Benjamin N A Calver Collier J Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995; 25:918–23.

15 Newby DE RA Wright Ludlam CA An in vivo model for the assessment of the acute fibrinolytic capacity of the endothelium. Thromb Haemostas 1997; 78:1242–8.

16 Newby DE DG Sciberras Mendel CM Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol 1997; 43:493–9.

17 Newby DE DG Sciberras Ferro CJ Substance P induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. Br J Clin Pharmacol 1999; 48:336–44.

18 Vane JR EE Anggard Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323:27–36.

19 Furchgott RF Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373–6.

20 Ludmer PL AP Selwyn Shook TL Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315:1046–51.

21 Celermajer DS KE Sorensen Gooch VM Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111–15.

22 Chowienczyk PJ GF Watts Cockcroft JR Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992; 340:1430–2.

23 Celermajer DS MR Adams Clarkson P Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996; 334:150–4.

24 Newby DE RA Wright Labinjoh C Endothelial dysfunction, impaired endogenous fibrinolysis and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999; 99:1411–15.

25 Vallance P J Collier Moncada S. Effects of endotheliumderived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; ii:997–1000.

26 Newby DE RA Wright Dawson P The L-arginine:nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res 1998; 38:485–92.

27 Cruden NLM KAA Fox Boon NA Endogenous fibrinolysis and response to thrombolytic therapy during acute myocardial infarction. Eur Heart J 2000; 21:P1096.

28 Newby DE AL McLeod Uren NG Coronary atherosclerosis impairs cardiac tissue plasminogen activator release: direct association between endothelial dysfunction and atherothrombosis. Circulation 2001; 103:1936–41.

29 Steins MB T Padro Li CX Overexpression of tissuetype plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 1999; 145:173–80.

30 Hamsten A B Wiman de Faire U Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557–63.

31 Ridker PM DE Vaughan Stampfer MJ Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341:1165–8.

32 Mann J Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999; 82:265–8.

33 Nomura H M Naito Iguchi A Fibrin gel induces the migration of smooth muscle cells from rabbit aortic explants. Thromb Haemost 1999; 82:1347-52.